The IMA Group Acquires Accelemed Research Institute

Transaction expands IMA’s footprint to more than 20 sites; growing its Southwest presence.

TARRYTOWN, N.Y.--(BUSINESS WIRE)--With its announcement of the acquisition of Accelemed Research Institute in Austin, TX, The IMA Group (IMA) continues to grow its presence in the Southwest and its capabilities in a broad range of clinical trials. The acquisition of Accelemed expands the company’s depth in multi-therapeutic clinical trial sites focused on cardiometabolic and GI diseases such as non-alcoholic steatohepatitis (NASH), obesity, high cholesterol, and diabetes. Terms of the transaction were not disclosed.

As its second Texas clinical research site and fifth in the Southwest, IMA continues to bring research opportunities to underserved and diverse communities throughout the United States. Overall, IMA Clinical Research now has 17 independent research sites nationally, including Texas, Arizona, New York, Nevada, and Florida, and 5 embedded within physician offices in Louisiana and North Carolina.

“We continually look for ways to ensure clinical trials are accessible and meaningful to the people who will most benefit from promising therapies and medications,” said Dr. Mark Weinberger, President and CEO of The IMA Group. “Accelemed’s focus on chronic, debilitating diseases and patient diversity complement the core capabilities of IMA’s therapeutic offerings and our commitment to expanded patient access.”

Accelemed’s CEO, Anvi Ta, NP, CPI, brings significant clinical experience to IMA Clinical Research and deep relationships in the greater Austin, Texas area. Anvi joins the IMA Clinical Research team as Senior Regional Director of Operations. A nurse practitioner by training, Anvi will continue to manage Accelemed while serving as a sub-investigator. The company will continue operating under its current name, with additional essential leadership, investigators and staff remaining.

“Our company is founded on the belief that clinical trials today bring hope for tomorrow,” said Ta. “Becoming part of IMA Clinical Research provides the centralized infrastructure that will enable us to continue that mission by expanding our focus on patient care across more areas and to more patients,” said Ta.

About IMA Clinical Research:

IMA Clinical Research, a division of The IMA Group, is a physician-founded network of comprehensive clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. With more than 150 sites in the IMA Clinical Trial Network, IMA Clinical Research has extensive capabilities to conduct site-based, hybrid and fully decentralized clinical trials that support the development of safe and effective new treatments. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects and a robust database of interested clinical trial participants for pharmaceutical and device sponsors. For more information, visit www.imaresearch.com or www.theIMAgroup.com. For more information about Accelemed Research Institute, visit Accelemed Research Institute.